Open-label study to verify effectiveness, safety of pegylated liposomal doxorubicin [doxorubicin liposomal] 50 mg/m2 administered every 4 weeks to patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) who have undergone prior platinum-based chemotherapy.

Trial Profile

Open-label study to verify effectiveness, safety of pegylated liposomal doxorubicin [doxorubicin liposomal] 50 mg/m2 administered every 4 weeks to patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) who have undergone prior platinum-based chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2010

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Apr 2010 Last checked against ClinicalTrials.gov record.
    • 30 Mar 2010 Actual patient number (74) added as reported by ClinicalTrials.gov.
    • 19 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top